XenoPort Announces FDA Agreement on a Special Protocol Assessment for a Pivotal Phase 3
XenoPort, Inc. (Nasdaq: XNPT) announced today that it had reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of arbaclofen placarbil (AP), previously …